Bepridil Hydrochloride
The hydrochloride salt of bepridil, a calcium channel blocker historically used for angina and heart rhythm disorders. It was withdrawn from widespread clinical use due to its risk of causing life-threatening ventricular arrhythmias, particularly in patients with underlying heart conditions. It remains a reference compound in cardiac research.
Molecular Weight
403.0000 g/mol
TPSA
15.70 Ų
Therapeutic Areas
Mechanism of Action
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
2D Structure
Cite this structure
Embed this structure
SMILES
CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1.Cl.O
InChI
InChI=1S/C24H34N2O.ClH.H2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22;;/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3;1H;1H2
Molecular Formula
C24H35ClN2O
HBD / HBA
1 / 3
Rotatable Bonds
10
Heavy Atoms
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
The hydrochloride salt of bepridil, a calcium channel blocker historically used for angina and heart rhythm disorders. It was withdrawn from widespread clinical use due to its risk of causing life-threatening ventricular arrhythmias, particularly in patients with underlying heart conditions. It remains a reference compound in cardiac research.
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Yes, Bepridil Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200382. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 50088. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bepridil-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bepridil-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bepridil-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bepridil-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bepridil-hydrochloride"></drugfyi-drug>